Evidence map›Paper›PMID 29037226›Full record

Trial reportTrials2017

Xingnaojing for Moderate-to-severe Acute ischemic Stroke (XMAS): study protocol for a randomized controlled trial.

Xinxing Lai, Kegang Cao, Lingbo Kong, Qiang Liu, Ying Gao, XMAS study investigators

Registry-linked trialOpen access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Trials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02728180 (Xingnaojing for Moderate-to-severe Acute Ischemic Stroke), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02728180 phase4unknown statusnot on this map

Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS): A Multicenter, Prospective, Randomized, Open-label, Blinded Endpoint Clinical Trial.

TypeinterventionalSponsorDongzhimen Hospital, BeijingRan2016 to 2019Enrolled720ConditionsAcute Ischemic StrokeArmsXingnaojing injection, Standard care
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Xinxing LaiDepartment of Neurology, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, 5 Haiyuncang, Dongcheng District, Beijing, 100029, China.
Kegang CaoDepartment of Neurology, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, 5 Haiyuncang, Dongcheng District, Beijing, 100029, China.
Lingbo KongInstitute for Cerebrovascular Disease of Beijing University of Chinese Medicine, 5 Haiyuncang, Dongcheng District, Beijing, 100029, China.
Qiang LiuCenter for Evidence-based Medicine, the Word Federation of Chinese Medicine Societies, 19 Xiaoying Road, Chaoyang District, Beijing, 100101, China.
Ying GaoDepartment of Neurology, Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine, 5 Haiyuncang, Dongcheng District, Beijing, 100029, China. gaoying973@163.com.ORCID http://orcid.org/0000-0001-6972-3846
XMAS study investigators
Beijing University of Chinese Medicine · CNDongzhimen Hospital Affiliated to Beijing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundXingnaojing injection (XNJ) is widely used for the treatment of stroke in China. However, there is currently a lack of high-quality evidence of its efficacy for acute ischemic stroke. The main objective of this study is to determine whether the addition of XNJ to standard care improves the 3-month functional outcome in patients with acute ischemic stroke (AIS). METHODS/

designThe XMAS study is a multicenter, prospective, randomized controlled, open-label trial with a blinded endpoints design. A total of 720 patients will be randomly allocated to either the intervention or the control group in a 1:1 ratio. The intervention group receives XNJ combined with standard care, and the control group receives standard care alone. XNJ will be administered intravenously every 12 h for 10 days. The primary outcome is the proportion of patients who are independent at 3 months after stroke onset defined as a modified Rankin Scale score of 0 to 2. Secondary outcomes include early neurological deterioration at 48 h, the change in National Institutes of Health Stroke Scale score, patient-reported outcome, symptomatic intracranial hemorrhage at 10 days, the Barthel Index score, deaths from any cause and cardiovascular events at 3 months. DISCUSSION: The results of this trial will provide critical evidence for XNJ in the treatment of AIS as a complementary approach that can be initiated after reperfusion therapy or when the AIS is not eligible for thrombolytic treatment.

trial registrationClinical Trials.gov, ID: NCT02728180 . Registered on 28 March 2016.

Indexed as

Activities of Daily LivingAdultAgedAged, 80 and overBrain IschemiaChinaDisability EvaluationDrugs, Chinese HerbalFemaleHumansMaleMiddle AgedProspective StudiesRecovery of FunctionResearch DesignSeverity of Illness IndexDrugs, Chinese HerbalxingnaojingAcute ischemic strokeChinese medicineRandomized controlled trialXingnaojing injection

Identifiers

PMID29037226
PMCPMC5644245
OpenAlexW2765699152

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.